| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Animal: RNA Viruses |
Unité Mixte CNRS/BioMérieux UMR 2142, Ecole Normale Supérieure, 46 Allée d’Italie, 69364 Lyon Cédex 07, France1
Microbiology and Tumorbiology Center, Karolinska Institute, S-171 77 Stockholm, Sweden2
Centre Européen de Recherche en Virologie et en Immunologie, CNRS/BioMérieux UMR 2142, 21 avenue Tony Garnier, 69007 Lyon, France3
Institut Pasteur, Unité d’Immunité Cellulaire Antivirale, Département SIDA-Rétrovirus, 28 rue du Dr Roux, Paris, France4
Author for correspondence: Geneviève Inchauspé. Fax +33 4 72 72 85 33. e-mail Genevieve.Inchauspe{at}ens-lyon.fr
The capacity of recombinant Semliki Forest virus particles (rSFV) expressing the hepatitis C virus non-structural protein 3 (NS3) to induce, in comparison or in combination with an NS3-expressing plasmid, specific cellular and humoral immune responses in murine models was evaluated. In vitro studies indicated that both types of vaccine expressed the expected size protein, albeit with different efficacies. The use of mice transgenic for the human HLA-A2.1 molecule indicated that the rSFV-expressed NS3 protein induces, as shown previously for an NS3 DNA vaccine, NS3-specific cytotoxic lymphocytes (CTLs) targeted at one dominant HLA-A2 epitope described in infected patients. All DNA/rSFV vaccine combinations evaluated induced specific CTLs, which were detectable for up to 31 weeks after the first injection. Overall, less than 1 log difference was observed in terms of the vigour of the bulk CTL response induced and the CTL precursor frequency between all vaccines (ranging from 1:2·6x105 to 1:1x106). Anti-NS3 antibodies could only be detected following a combined vaccine regimen in non-transgenic BALB/c mice. In conclusion, rSFV particles expressing NS3 are capable of inducing NS3-specific cellular immune responses targeted at a major HLA-A2 epitope. Such responses were comparable to those obtained with a DNA-based NS3 vaccine, whether in the context of single or combined regimens.
This article has been cited by other articles:
|
|
 |
|
  A. M. Majid, H. Ezelle, S. Shah, and G. N. Barber Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine Vehicle J. Virol., July 15, 2006; 80(14): 6993 - 7008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karayiannis, J. Main, and H. C. Thomas Hepatitis vaccines Br. Med. Bull., August 31, 2004; 70(1): 29 - 49. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yu, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3 J. Gen. Virol., June 1, 2004; 85(6): 1533 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiao, R. Y.-H. Wang, Q. Qiu, H. J. Alter, and J. W.-K. Shih Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes J. Gen. Virol., June 1, 2004; 85(6): 1545 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Himoudi, J.-D. Abraham, A. Fournillier, Y. C. Lone, A. Joubert, A. O. De Beeck, D. Freida, F. Lemonnier, M. P. Kieny, and G. Inchauspe Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection J. Virol., November 13, 2002; 76(24): 12735 - 12746. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
